All In Biotech

Drug Trial Radar · NCT00613457

Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With Acute Lymphoblastic Leukemia

AIEOP LLA 2000 Multicenter Study for the Diagnosis and Treatment of Childhood Acute Lymphoblastic Leukemia

Last checked: Nov 19, 2026Latest source record: Jan 14, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,039 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,039

Actual

Start

Sep 2000

Primary completion

Jul 2006

Study completion Jul 2006

Sponsor

Lead sponsor
Associazione Italiana Ematologia Oncologia PediatricaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 13, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 1 year, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating young patients with acute lymphoblastic leukemia. PURPOSE: Thisphase III trial is studying several different combination chemotherapy regimens to compare how well they work in treating young patients with acute lymphoblastic leukemia.

Conditions

  • Leukemia

Interventions

  • dexamethasoneDrug

    10 mg/sqm/day from for 21 days

  • asparaginaseDrug

    native E-coli Asparaginase 5,000 IU/sqm x 8 doses

  • AsparaginaseDrug

    native E-Coli Asparaginase 10,000 IU/sqm x 4 doses

  • cyclophosphamideDrug

    1,000 mg/sqm i.v. 2 doses in Induction phase 1000 mg/sqm i.v. 1 dose in Protocoll II 500 mg/sqm i.v. 1 dose in protocol III

  • cytarabineDrug

    75 mg/sqm i.v.or s.c. 4 doses/week for 4 weeks in Induction phase 75 mg/sqm i.v.or s.c. 4 doses/week for 2 weeks in Protocol II and III

  • daunorubicinDrug

    30 mg/sqm i.v. 4 doses in Induction phase

  • doxorubicinDrug

    30 mg/sqm i.v. x 4 doses in Protocol II and III

  • EtoposideDrug

    100 mg/sqm i.v. for 3 doses in HR block 3

  • IfosfamideDrug

    800 mg/sqm i.v.q12h x 5 in HR block 2

  • mercaptopurineDrug

    60 mg/sqm p.o. c 28 days in Induction phase 60 mg/sqm p.o. x 56 days in Protocol M 50 mg/sqm daily in Maintenance phase

  • MethotrexateDrug

    by age i.t. in Induction/Protocol M/Protocol II/Protocol III/HR Blocks and maintenance

  • prednisoneDrug

    60 mg/sqm daily p.o. for 28 days then tapered in Induction phase

  • thioguanineDrug

    60 mg/sqm p.o. x 14 days in Protocol II and Protocol III

  • VincristineDrug

    1.5 mg/sqm i.v. x 4 doses in Induction phase and Protocol II 1.5 mg/sqm i.v. x 2 doses in Protocol III and HR block 1

  • VindesineDrug

    3 mg/sqm i.v. x 2 doses in HR block 2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of dexamethasone vs prednisone during the induction phaseTime frame: 5 years
  2. Event-free survival (EFS) and overall survival after initial remission in intermediate-risk and high-risk patientsTime frame: 5 years
  3. Safety and efficacy of treatment reduction during reintensification in standard-risk patientsTime frame: 5 years
  4. EFS after second delayed reintensification in intermediate-risk patientsTime frame: 5 years
  5. Outcome after extended reintensification therapy in high-risk patientsTime frame: 5 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.